SCHEMBL165053

SCHEMBL165053

Cc1cccc(Cl)c1NC(=O)Nc1ccc(-c2cnc(C3CCC(OC=O)CC3)s2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 4/20 0.42
LCK P06239 7/20 0.42
MAPK14 Q16539 5/20 0.42
RAF1 P04049 1/20 0.42
MAPK13 O15264 1/20 0.42
EGFR P00533 1/20 0.42
FYN P06241 1/20 0.42
HCK P08631 1/20 0.42
SRC P12931 1/20 0.42
JAK3 P52333 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
EPHB4 P54760 2/20 0.40
CNR1 P21554 1/20 0.39
PYGL P06737 1/20 0.39
KDR P35968 2/20 0.38
TEK Q02763 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL174149 0.88 DGAT1 (0.55) DGAT1NPSR1EPHB4CNR1KDR
SCHEMBL174659 0.87 CNR1 (0.49) DGAT1CNR1KDR
SCHEMBL161039 0.87 LCK (0.46) DGAT1LCKMAPK14RAF1MAPK13
SCHEMBL165052 0.87 DGAT1 (0.55) DGAT1LCKMAPK14MAPK13EGFR
SCHEMBL162707 0.87 DGAT1 (0.44) DGAT1EGFREPHB4CNR1KDR
SCHEMBL163680 0.86 DGAT1 (0.47) DGAT1NPSR1EPHB4CNR1TEK
SCHEMBL173788 0.85 KDR (0.45) DGAT1EGFREPHB4CNR1KDR
SCHEMBL161468 0.85 DGAT1 (0.42) DGAT1KDR
SCHEMBL162339 0.84 MAPT (0.42) DGAT1CNR1KDR
SCHEMBL159427 0.82 DGAT1 (0.44) DGAT1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP claimed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US claimed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO claimed
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 DGAT1 1/4885LCK 2899/4885MAPK14 2261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.